Abstract: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Abstract: The present invention encompasses nucleic acids, methods, compositions, and kits for sensitive, rapid and specific detection of Mycoplasma, Acholeplasma, Ureaplasma, Phytoplasma and Spiroplasma species in a sample. The invention utilizes specific primers and amplification methods that permit differentiation between species due to specific amplification of target nucleic acids of contaminating Mollicute cells. In one embodiment, the invention utilizes the differing melting temperatures (Tm) of various potential PCR products to identify whether they are specific target amplification products, non-specific, non-target amplification products, specific positive control products, or primer-dimer products.

Abstract: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Abstract: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Abstract: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Abstract: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Abstract: The present invention encompasses nucleic acids, methods, compositions, and kits for sensitive, rapid and specific detection of Mycoplasma, Acholeplasma, Ureaplasma, Phytoplasma and Spiroplasma species in a sample. The invention utilizes specific primers and amplification methods that permit differentiation between species due to specific amplification of target nucleic acids of contaminating Mollicute cells. In one embodiment, the invention utilizes the differing melting temperatures (Tm) of various potential PCR products to identify whether they are specific target amplification products, non-specific, non-target amplification products, specific positive control products, or primer-dimer products.

Abstract: The present invention relates to a PCR (polymerase chain reaction) based assay that is useful for detecting, identifying, quantitating and analysis of a target nucleic acid (target nucleic acid hereinafter) in a sample. More specifically, the present invention relates to a PCR based assay that can improve accuracy in detecting, identifying, and quantitating contamination in mammalian cell lines using a PCR-based assay of nucleic acid oligonucleotides (oligoprobes) having a sequence expected to be complementary to a target nucleic acid sequence in a sample. More specifically, the sample may contain either cells or nucleic acid isolated from a cell line. The present invention also relates to a detection kit using the PCR-based assay.